Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial
- 22 July 2016
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 17 (9), 1272-1282
- https://doi.org/10.1016/s1470-2045(16)30166-8
Abstract
No abstract availableThis publication has 25 references indexed in Scilit:
- Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trialThe Lancet Oncology, 2012
- RASMutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF InhibitorsThe New England Journal of Medicine, 2012
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationThe New England Journal of Medicine, 2011
- Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium studyThe Lancet Oncology, 2010
- Inhibition of Mutated, Activated BRAF in Metastatic MelanomaThe New England Journal of Medicine, 2010
- New Agents in the Treatment for Malignancies of the Salivary and Thyroid GlandsHematology/Oncology Clinics of North America, 2008
- Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II StudyJournal of Clinical Oncology, 2008
- Motesanib Diphosphate in Progressive Differentiated Thyroid CancerThe New England Journal of Medicine, 2008
- BRAF mutation in thyroid cancerEndocrine-Related Cancer, 2005
- Frequency of BRAF T1796A mutation in papillary thyroid carcinoma relates to age of patient at diagnosis and not to radiation exposureThe Journal of Pathology, 2005